Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelyrin, Alumis, Atai, Alvotech, Concentra, Psilera, Teva.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Celltrion, Ensho, Johnson & Johnson, Meiragtx, Sensorion.
New hires and promotions in the biopharma industry, including: Atea, BTB, Climb, Diamedica, Immunoprecise, Inhibikase, Nuclera, Tivic, Werewolf, Xeris.
Researchers have altered the genetic code in a strain of Escherichia coli, reducing the number of stop codons from three to one and assigning the freed-up stop codons to nonstandard amino acids. They reported on the recoded bacterium, which they named OCHRE, in Nature on Feb. 5, 2025.
Though it’s been used off-label for more than three decades to treat cerebrotendinous xanthomatosis, Mirum Pharmaceuticals Inc.’s chenodiol gained an official U.S. FDA nod Feb. 21 as the first drug approved specifically for treating the rare autosomal recessive lipid storage disease.
RSS
